Description
In 1994, we reported a 3.4 +/- 0.8 year follow-up of the eight patients who experienced remission of nephrotic syndrome during the Collaborative Study Group-sponsored, multicenter trial of captopril therapy in patients with type 1 diabetes with nephropathy (Captopril Study). Of the 409 patients randomized to treatment on the Captopril Study, 108 had nephrotic syndrome (24-hour proteinuria \textgreater/= 3.5 g of protein) at baseline. Of these 108 patients, 8 experienced remission of nephrotic syndrome (proteinuria
Subject
Adult; Angiotensin-Converting Enzyme Inhibitors/*therapeutic use; Antihypertensive Agents/*therapeutic use; Blood Pressure/drug effects; Captopril/*therapeutic use; Chronic/etiology; Creatinine/blood; Diabetes Mellitus; Diabetic Nephropathies/*drug therapy/physiopathology; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Failure; Male; Middle Aged; Nephrotic Syndrome/complications/*drug therapy/physiopathology; Prospective Studies; Proteinuria; Randomized Controlled Trials as Topic; Remission Induction; Type 1/*complications